Shenzhen GeneMind Biosciences Co., Ltd, a health tech firm that delivers gene sequencing tools for clinical applications, announced on Wednesday that it has garnered 410 million yuan ($64 million) in a Series B+ round of financing.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
